Frontlight ResearchEarly access
What researchers published on Burkitt lymphoma
1,933 papers, newest first.
Showing 20 of 31
Trial resultNovel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.Blood advances
Randomised trialRituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.European journal of haematology
Randomised trialR-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.The Lancet. Haematology
Trial resultNext-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.Blood cancer journal
Trial resultBlinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.American journal of hematology
Trial resultCD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.Blood
Trial resultA novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia.American journal of hematology
Trial resultBlinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.Pediatric blood & cancer
Trial resultPreferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.Blood advances
Trial resultEfficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.Blood
Trial resultSequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.Blood advances
Trial resultIKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial.Blood advances
Trial resultCAR19/22 T cell therapy in adult refractory Burkitt's lymphoma.Cancer immunology, immunotherapy : CII
Trial resultA dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the "CARMEN" phase II trial.British journal of haematology
Trial resultFavourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.Annals of oncology : official journal of the European Society for Medical Oncology
Trial resultMean platelet counts are relatively decreased with malaria but relatively increased with endemic Burkitt Lymphoma in Uganda, Tanzania, and Kenya.British journal of haematology
Trial resultRituximab is highly effective in children and adolescents with Burkitt lymphoma in Risk Groups R2 to R4.Pediatric hematology and oncology
Trial resultClinicopathologic Characterization of Children With B-Cell Non-Hodgkin Lymphoma Over 10 Years at a Tertiary Center in Cape Town, South Africa.Journal of pediatric hematology/oncology
Trial resultEarly response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells.Blood
Trial resultExperience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.British journal of haematology